Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reducing primary melanoma mortality

E C Borden1

  • 1Center for Cancer Drug Discovery and Development, The Cleveland Clinic Foundation, T40, 9500 Euclid Avenue, Cleveland, OH 44195, USA. bordene@cc.ccf.org

Current Oncology Reports
|December 21, 2000
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Oncogene·2012
Same author

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.

Oncogene·2011
Same author

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.

British journal of cancer·2011
Same author

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.

Oncogene·2007
Same author

Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.

Clinical pharmacology and therapeutics·2007
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles